Data as of Aug 20
| -0.04 / -0.04%|
The 14 analysts offering 12-month price forecasts for United Therapeutics Corp have a median target of 100.50, with a high estimate of 165.00 and a low estimate of 65.00. The median estimate represents a +7.75% increase from the last price of 93.27.
The current consensus among 15 polled investment analysts is to Hold stock in United Therapeutics Corp. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.